Theravance Biopharma (NASDAQ:TBPH) Stock Price Expected to Rise, TD Cowen Analyst Says

Theravance Biopharma (NASDAQ:TBPH) had its price target raised by TD Cowen from $13.00 to $15.00 in a research note issued on Monday,Benzinga reports. The brokerage presently has a “hold” rating on the biopharmaceutical company’s stock. TD Cowen’s target price would suggest a potential upside of 2.10% from the stock’s current price.

TBPH has been the subject of a number of other reports. Wall Street Zen cut Theravance Biopharma from a “buy” rating to a “hold” rating in a research report on Saturday. Oppenheimer lowered shares of Theravance Biopharma from an “outperform” rating to a “market perform” rating in a research report on Thursday, March 5th. BTIG Research reiterated a “buy” rating and issued a $21.00 price target on shares of Theravance Biopharma in a research report on Friday. HC Wainwright raised their price objective on shares of Theravance Biopharma from $20.00 to $27.00 and gave the stock a “buy” rating in a research report on Monday, March 2nd. Finally, B. Riley Financial restated a “neutral” rating and issued a $14.00 price objective (down from $28.00) on shares of Theravance Biopharma in a research note on Wednesday, March 4th. Two analysts have rated the stock with a Strong Buy rating, two have assigned a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $21.33.

Theravance Biopharma Trading Up 2.5%

NASDAQ:TBPH traded up $0.36 during midday trading on Monday, hitting $14.69. 235,581 shares of the company were exchanged, compared to its average volume of 618,360. Theravance Biopharma has a fifty-two week low of $7.90 and a fifty-two week high of $21.03. The company has a market capitalization of $744.39 million, a PE ratio of 7.24 and a beta of 0.17. The company has a fifty day simple moving average of $18.00 and a 200 day simple moving average of $16.89.

Insider Activity

In related news, SVP Rhonda Farnum sold 31,067 shares of the stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $13.96, for a total transaction of $433,695.32. Following the completion of the transaction, the senior vice president directly owned 232,699 shares of the company’s stock, valued at $3,248,478.04. This represents a 11.78% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. 6.90% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Theravance Biopharma

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Arrowstreet Capital Limited Partnership purchased a new stake in shares of Theravance Biopharma during the 3rd quarter worth approximately $10,611,000. Assenagon Asset Management S.A. raised its holdings in Theravance Biopharma by 1,629.4% during the third quarter. Assenagon Asset Management S.A. now owns 414,715 shares of the biopharmaceutical company’s stock worth $6,055,000 after purchasing an additional 390,735 shares during the last quarter. Pacer Advisors Inc. acquired a new position in Theravance Biopharma during the fourth quarter worth $6,342,000. Hillsdale Investment Management Inc. purchased a new stake in Theravance Biopharma during the third quarter worth $4,536,000. Finally, Janus Henderson Group PLC boosted its position in Theravance Biopharma by 214.8% during the fourth quarter. Janus Henderson Group PLC now owns 400,496 shares of the biopharmaceutical company’s stock worth $7,493,000 after purchasing an additional 273,288 shares in the last quarter. Institutional investors and hedge funds own 99.10% of the company’s stock.

Theravance Biopharma Company Profile

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.